Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gretchen Tamms

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2007
Quadrivalent human papillomavirus vaccineEliav Barr, Gretchen Tamms
Expert Review of Vaccines|December 19, 2023
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and childrenTimothy J Chapman, Liset Olarte, Ghassan Dbaibo, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
Vaccine|August 7, 2004
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineKevin A Ault, Anna R Giuliano, Robert P Edwards, et al.
Vaccines|February 26, 2025
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of AgeTosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccines|October 28, 2025
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. <i>Vaccines</i> 2025, <i>13</i>, 192Tosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
The Pediatric Infectious Disease Journal|August 11, 2023
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three StudiesTimothy J Chapman, Shrita M Patel, Sheryl A Flores, et al.
The Journal of Infectious Diseases|September 20, 2019
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsStuart P Adler, Nicole Lewis, Anthony Conlon, et al.
Open Forum Infectious Diseases|February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2007
Quadrivalent human papillomavirus vaccineEliav Barr, Gretchen Tamms
Expert Review of Vaccines|December 19, 2023
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and childrenTimothy J Chapman, Liset Olarte, Ghassan Dbaibo, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
Vaccine|August 7, 2004
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineKevin A Ault, Anna R Giuliano, Robert P Edwards, et al.
Vaccines|February 26, 2025
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of AgeTosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccines|October 28, 2025
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. <i>Vaccines</i> 2025, <i>13</i>, 192Tosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
The Pediatric Infectious Disease Journal|August 11, 2023
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three StudiesTimothy J Chapman, Shrita M Patel, Sheryl A Flores, et al.
The Journal of Infectious Diseases|September 20, 2019
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative SubjectsStuart P Adler, Nicole Lewis, Anthony Conlon, et al.
Open Forum Infectious Diseases|February 11, 2022
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)Laura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Pageof 2